Intellia Therapeutics (38I) Stock Forecast & Price Target

Compare

13 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

38I Analyst Ratings

Moderate Buy

16 Buy

4 Hold

1 Sell

Based on 21 analysts giving stock ratings to

Intellia

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

38I Stock 12 Month Forecast

Average Price Target

€26.34

▲(287.99%Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is €26.34 with a high forecast of €56.25 and a low forecast of €6.92. The average price target represents a 287.99% change from the last price of €6.79.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","18":"€18","31":"€31","44":"€44","57":"€57"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56.25426235,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€56.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.3443037836,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€26.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.92360152,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.92</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,18,31,44,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.522,10.347558642307693,14.173117284615385,17.998675926923077,21.824234569230768,25.64979321153846,29.475351853846156,33.30091049615385,37.12646913846154,40.95202778076923,44.77758642307692,48.603145065384616,52.42870370769231,{"y":56.25426235,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.522,8.046792598738461,9.571585197476923,11.096377796215386,12.621170394953847,14.145962993692308,15.670755592430769,17.19554819116923,18.72034078990769,20.245133388646153,21.769925987384614,23.294718586123075,24.81951118486154,{"y":26.3443037836,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.522,6.552892424615385,6.58378484923077,6.614677273846154,6.645569698461538,6.676462123076924,6.707354547692308,6.738246972307692,6.769139396923077,6.800031821538462,6.830924246153846,6.8618166707692305,6.892709095384616,{"y":6.92360152,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.17,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.86,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.83,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.845,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.54,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.525,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.06,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.952,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.234,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.522,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€56.25

Average Price Target€26.34

Lowest Price Target€6.92

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yanan ZhuWells Fargo

Wells Fargo

€43.29

Buy

537.61%

Upside

Reiterated

06/13/25

Intellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating

William PickeringBernstein

Bernstein

€38.96→€12.12

Buy

78.53%

Upside

Reiterated

06/05/25

Bernstein Remains a Buy on Intellia Therapeutics (NTLA)

Whitney IjemCanaccord Genuity

Canaccord Genuity

€64.07→€46.76

Buy

588.62%

Upside

Reiterated

06/02/25

Intellia Therapeutics price target lowered to $54 from $74 at CanaccordIntellia Therapeutics price target lowered to $54 from $74 at Canaccord

Debanjana ChatterjeeJonesTrading

JonesTrading

€28.57→€21.65

Buy

218.80%

Upside

Reiterated

05/30/25

Intellia's Phase 3 Programs Progress Unhindered Despite Safety Concerns

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/29/25

Truist Financial Remains a Buy on Intellia Therapeutics (NTLA)

Liisa BaykoEvercore ISI

Evercore ISI

€41.56

Buy

512.10%

Upside

Reiterated

05/29/25

Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

Salveen RichterGoldman Sachs

Goldman Sachs

€6.93

Sell

2.02%

Upside

Reiterated

05/29/25

Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

05/29/25

Positive Outlook for Intellia Therapeutics Despite Safety Concerns in MAGNITUDE Trial

Silvan TuerkcanCitizens JMP

Citizens JMP

―

Hold

―

Reiterated

05/29/25

Citizens JMP Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

Joseph ThomeTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/29/25

TD Cowen Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

Brian ChengJ.P. Morgan

J.P. Morgan

€10.39

Hold

53.03%

Upside

Reiterated

05/29/25

J.P. Morgan Remains a Hold on Intellia Therapeutics (NTLA)

Rick BienkowskiCantor Fitzgerald

Cantor Fitzgerald

€56.28

Buy

728.89%

Upside

Reiterated

05/29/25

Cantor Fitzgerald Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

€25.98

Buy

282.56%

Upside

Reiterated

05/29/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Savara (NASDAQ: SVRA) and Intellia Therapeutics (NASDAQ: NTLA)

Alec StranahanBank of America Securities

Bank of America Securities

€37.23→€33.77

Buy

397.33%

Upside

Reiterated

05/28/25

Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study

Mani ForooharLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/28/25

Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yanan ZhuWells Fargo

Wells Fargo

€43.29

Buy

537.61%

Upside

Reiterated

06/13/25

Intellia Therapeutics: Expert Confidence in Addressing Liver Enzyme Concerns Supports Buy Rating

William PickeringBernstein

Bernstein

€38.96→€12.12

Buy

78.53%

Upside

Reiterated

06/05/25

Bernstein Remains a Buy on Intellia Therapeutics (NTLA)

Whitney IjemCanaccord Genuity

Canaccord Genuity

€64.07→€46.76

Buy

588.62%

Upside

Reiterated

06/02/25

Intellia Therapeutics price target lowered to $54 from $74 at CanaccordIntellia Therapeutics price target lowered to $54 from $74 at Canaccord

Debanjana ChatterjeeJonesTrading

JonesTrading

€28.57→€21.65

Buy

218.80%

Upside

Reiterated

05/30/25

Intellia's Phase 3 Programs Progress Unhindered Despite Safety Concerns

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/29/25

Truist Financial Remains a Buy on Intellia Therapeutics (NTLA)

Liisa BaykoEvercore ISI

Evercore ISI

€41.56

Buy

512.10%

Upside

Reiterated

05/29/25

Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

Salveen RichterGoldman Sachs

Goldman Sachs

€6.93

Sell

2.02%

Upside

Reiterated

05/29/25

Intellia Therapeutics Faces Safety and Efficacy Challenges with Nex-Z: Analyst Issues Sell Rating

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

05/29/25

Positive Outlook for Intellia Therapeutics Despite Safety Concerns in MAGNITUDE Trial

Silvan TuerkcanCitizens JMP

Citizens JMP

―

Hold

―

Reiterated

05/29/25

Citizens JMP Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

Joseph ThomeTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/29/25

TD Cowen Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

Brian ChengJ.P. Morgan

J.P. Morgan

€10.39

Hold

53.03%

Upside

Reiterated

05/29/25

J.P. Morgan Remains a Hold on Intellia Therapeutics (NTLA)

Rick BienkowskiCantor Fitzgerald

Cantor Fitzgerald

€56.28

Buy

728.89%

Upside

Reiterated

05/29/25

Cantor Fitzgerald Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

€25.98

Buy

282.56%

Upside

Reiterated

05/29/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Savara (NASDAQ: SVRA) and Intellia Therapeutics (NASDAQ: NTLA)

Alec StranahanBank of America Securities

Bank of America Securities

€37.23→€33.77

Buy

397.33%

Upside

Reiterated

05/28/25

Intellia Therapeutics: Buy Rating Affirmed Despite Safety Concerns in MAGNITUDE Study

Mani ForooharLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/28/25

Intellia Therapeutics: Positive Outlook and Strong Enrollment Support Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

1 Month

xxx

Success Rate

5/13 ratings generated profit

Average Return

+2.22%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 38.46% of your transactions generating a profit, with an average return of +2.22% per trade.

3 Months

xxx

Success Rate

15/37 ratings generated profit

Average Return

+13.34%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.54% of your transactions generating a profit, with an average return of +13.34% per trade.

1 Year

Geulah LivshitsChardan Capital

Success Rate

13/37 ratings generated profit

Average Return

+87.78%

reiterated a buy rating 7 months ago

Copying Geulah Livshits's trades and holding each position for 1 Year would result in 35.14% of your transactions generating a profit, with an average return of +87.78% per trade.

2 Years

xxx

Success Rate

13/37 ratings generated profit

Average Return

+100.41%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.14% of your transactions generating a profit, with an average return of +100.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

38I Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 38I has received 33 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. 38I average Analyst price target in the past 3 months is 26.34.

Each month's total comprises the sum of three months' worth of ratings.

38I Financial Forecast

38I Earnings Forecast

Next quarter’s earnings estimate for 38I is -€0.92 with a range of -€1.16 to -€0.54. The previous quarter’s EPS was -€0.98. 38I beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.00% of the time in the same period. In the last calendar year 38I has Outperformed its overall industry.

38I Sales Forecast

Next quarter’s sales forecast for 38I is €10.65M with a range of €0.00 to €44.44M. The previous quarter’s sales results were €14.78M. 38I beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.53% of the time in the same period. In the last calendar year 38I has Outperformed its overall industry.

38I Stock Forecast FAQ

What is DE:38I’s average 12-month price target, according to analysts?

Based on analyst ratings, Intellia Therapeutics Inc’s 12-month average price target is 26.34.

What is DE:38I’s upside potential, based on the analysts’ average price target?

Intellia Therapeutics Inc has 287.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Intellia Therapeutics Inc a Buy, Sell or Hold?

Intellia Therapeutics Inc has a consensus rating of Moderate Buy, which is based on 16 buy ratings, 4 hold ratings and 1 sell ratings.

What is Intellia Therapeutics Inc’s share price target?

The average share price target for Intellia Therapeutics Inc is 26.34. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €56.25 ,and the lowest forecast is €6.92. The average share price target represents 287.99% Increase from the current price of €6.79.

What do analysts say about Intellia Therapeutics Inc?

Intellia Therapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Intellia Therapeutics Inc?

To buy shares of DE:38I, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Intellia Therapeutics (38I) Stock Forecast & Price Target

38I Analyst Ratings

38I Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Intellia Therapeutics

38I Analyst Recommendation Trends

38I Financial Forecast

38I Earnings Forecast

38I Sales Forecast

38I Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts